Latest news with #ADHC
Globe and Mail
4 days ago
- Business
- Globe and Mail
GlucoGuard Receives $43 Million Enterprise Valuation Research Report
Del Mar, California--(Newsfile Corp. - June 10, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC). The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .0012 equivalent to a $43 million enterprise valuation, assuming full dilution for required developmental capital at the current stock price. As the stock price increases, the dilution would decline accordingly raising the price target. Currently, ADHC is working with Investment Partners on Capital Formation that will benefit the enterprise valuation model utilizing non-dilutive or controlled dilutive financial models. As the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition. A main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels. To access the research report, please visit the Harbinger Research website at: 2023-06-02 American Diversified Holdings Corp. Coverage Initiation Report ( "Management views the $43 M enterprise value to be conservative due to ability of the GlucoGuard technology to meet the unmet need of hypoglycemia and the severe problems of "Death in Bed"," commented ADHC. "Additionally, this report does not incorporate GlucoGuards' AI and Predictive learning software components and related IP due to its developing nature," concluded ADHC. Key Aspects of the Report 537mm Diabetic Patients Worldwide. 37 mm Diabetic Patients In the US. 3.7 Type 1 Diabetics in the US. 190k to 380K Potential Patients in the US. a potential market of $360 MM to $720MM in revenues. IN ADDITIONAL NEWS ADHC is in negotiations for a strategic partnership to license the GlucoGuard Technology to the Eurpean Union for upfront cash payments, milestone cash payments and cash payment royalties from revenues. Arete Biosciences development contract has been initially funded and is expected to expand into patient studies. ADHC 6-15-25 Quartely disclosure filing is expected to be filed this week ahead of the deadline. Dexcom APP integration and AI software system is under review and should be proceeding to the next phase in the near term. Patent Counsel is updating GlucoGuards' IP with the USPTO. Shareholders should anticipate and continual stream of announcements on these developments and more in the near future. About Harbinger Research, LLC Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation. The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see for more information. To view our disclosures and disclaimers, or for more information, visit Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@ GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. To view an enhanced version of this graphic, please visit: To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098 Email: JC@ ADHCInvestor@ SOCIAL MEDIA TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
Yahoo
4 days ago
- Business
- Yahoo
GlucoGuard Receives $43 Million Enterprise Valuation Research Report
Del Mar, California--(Newsfile Corp. - June 10, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC). The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .0012 equivalent to a $43 million enterprise valuation, assuming full dilution for required developmental capital at the current stock price. As the stock price increases, the dilution would decline accordingly raising the price target. Currently, ADHC is working with Investment Partners on Capital Formation that will benefit the enterprise valuation model utilizing non-dilutive or controlled dilutive financial models. As the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition. A main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels. To access the research report, please visit the Harbinger Research website at: 2023-06-02 American Diversified Holdings Corp. Coverage Initiation Report ( "Management views the $43 M enterprise value to be conservative due to ability of the GlucoGuard technology to meet the unmet need of hypoglycemia and the severe problems of "Death in Bed"," commented ADHC. "Additionally, this report does not incorporate GlucoGuards' AI and Predictive learning software components and related IP due to its developing nature," concluded ADHC. Key Aspects of the Report 537mm Diabetic Patients Worldwide. 37 mm Diabetic Patients In the US. 3.7 Type 1 Diabetics in the US. 190k to 380K Potential Patients in the US. a potential market of $360 MM to $720MM in revenues. IN ADDITIONAL NEWS ADHC is in negotiations for a strategic partnership to license the GlucoGuard Technology to the Eurpean Union for upfront cash payments, milestone cash payments and cash payment royalties from revenues. Arete Biosciences development contract has been initially funded and is expected to expand into patient studies. ADHC 6-15-25 Quartely disclosure filing is expected to be filed this week ahead of the deadline. Dexcom APP integration and AI software system is under review and should be proceeding to the next phase in the near term. Patent Counsel is updating GlucoGuards' IP with the USPTO. Shareholders should anticipate and continual stream of announcements on these developments and more in the near future. About Harbinger Research, LLC Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation. The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see for more information. To view our disclosures and disclaimers, or for more information, visit Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@ ABOUT GLUCOGUARD GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. For more information, visit: Contact: Phone: 817-525-0057Email: info@ To view an enhanced version of this graphic, please visit: To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098 Email: JC@ ; ADHCInvestor@ SOCIAL MEDIA TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. SOURCE: American Diversified Holdings Corporation To view the source version of this press release, please visit
Yahoo
02-06-2025
- Business
- Yahoo
Harbinger Research Publishes Coverage Initiation Report, on American Diversified Holdings Corporation (ADHC) and Its Operating Division, GlucoGuard
Prepared by Brian R. Connell, CFA, the report offers an in-depth analysis of the Company's business, industry, and growth opportunities as well as an analysis of ADHC potential future value Del Mar, California--(Newsfile Corp. - June 2, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC). The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. To access the research report, please visit the Harbinger Research website at: "This report will provide all interested stakeholders a comprehensive overview of ADHC's operations and a deep look into the potential of GlucoGuard's technology including a detailed valuation estimate," Commented ADHC. "This report will serve as the foundation to our future growth from highly respected Chartered Financial Analyst (CFA). As ADHC's growth propels the company into the major wall street arena this report with serve to open the door to high profile partnerships involving strategic partnerships with financial institutions focused on Mergers, Acquisitions and Corporate Finance." Concluded ADHC About Harbinger Research, LLC Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation. The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see for more information. To view our disclosures and disclaimers, or for more information, visit Harbinger Research was compensated in the amount of $5,000 for the preparation and distribution of this report. Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@ ABOUT GLUCOGUARD GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. For more information, visit: Contact: Phone: 817-525-0057Email: info@ To view an enhanced version of this graphic, please visit: To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098Email: JC@ ADHCInvestor@ SOCIAL MEDIA TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
Del Mar, California--(Newsfile Corp. - May 27, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that GlucoGuard has completed the Level 2 App integration through DEXCOM's Developer Program. The project development is in conjunction with UC Irvine's MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a). The Dexcom Developer Program is a partnership program that allows developers to access Dexcom API and integrate Dexcom CGM data into their own applications. Dexcom partners with the company to gain access to app credentials, sand box data, and development support. The Dexcom API allows partners to integrate DEXCOM CGM Data, such as glucose levels, into their applications. It is expected that in mid-June the next level of App integration development will be approved resulting in a fully functional back-end to front-end completion where the app will run on a mobile device. Developments Include: A functional front-end and back-end App capable of running on an emulator. A trained predictive algorithm for detecting hypoglycemia episodes with 95% accuracy. Secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data. GlucoGuard is also developing a suite of AI features designed to predict negative blood glucose events and mitigate these events before the patient suffers catastrophic adverse effects. The ability to manage glucose in this manner is a groundbreaking advancement that will truly establish GlucoGuard as a revolutionary technology in the field of diabetes – a multibillion-dollar industry. "We are very appreciative to all our partners in reaching these milestones," commented ADHC. "Developments are progressing rapidly and the GlucoGuard team is very grateful for the amazing support from all of our stakeholders." ABOUT GLUCOGUARD GlucoGuardTo view an enhanced version of this graphic, please visit: ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest. ABOUT ARETE BIOSCIENCES, Inc. Arete To view an enhanced version of this graphic, please visit: Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space. Arete BioScience includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries. ABOUT UCI CALIT 2 UCI CALIT2 To view an enhanced version of this graphic, please visit: Created in 2000, the California Institute for Telecommunications and Information Technology – known as CALIT2 – is one of four Gray Davis Institutes for Science and Innovation located on University of California campuses. The founding objective of CALIT2 was to create a world-class multidisciplinary research institute to promote discovery and innovation, notably to harness the ubiquity and scale of the internet and wireless technologies to accelerate growth in many different scientific areas and industries that are undergoing a massive transformation. Over two decades, CALIT2 has focused on transdisciplinary approaches of significant scale and complexity, as well as the creation of new, advanced scientific facilities, technical staff opportunities, and centers and 'living laboratories' to attract and support the nearly 250 UCI faculty who have opted to affiliate with the institute ABOUT DEXCOM Dexcom To view an enhanced version of this graphic, please visit: Dexcom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. COMPANY OVERVIEW Key Development PartnershipsThe GlucoGuard system is being developed in collaboration with three key partners: A leading U.S. research university, UNIVERSITY OF CALIFORNIA IRVINE. A highly respected biomedical engineering firm, ARETE BIOSCIENCE. A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector DEXCOM. Further details on these collaborations will be disclosed soon. CUTTING-EDGE TECHNOLOGY FOR UNMET MEDICAL NEEDSGlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest. ABOUT ARTIFICIAL INTELLIGENCE AND HEALTHCAREA recent report from the Mayo Clinic identified three potential benefits of AI in healthcare: Improving outcomes for both patients and clinical teams Lowering healthcare costs Benefitting population health From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment. Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45-minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis. Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care. See AI in healthcare: The future of patient care and health management - Mayo Clinic Press. ABOUT THE DIABETES MARKETThe diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption. For more information on the $28 billion diabetes market, visit: United States Diabetes Market Report. The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions. For details on the CGM market, visit: Continuous Glucose Monitoring Market. Image 1 To view an enhanced version of this graphic, please visit: ABOUT GLUCOGUARDGlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. For more information, visit: Phone: 817-525-0057Email: info@ Image 2 To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEOAmerican Diversified Holdings CorporationTelephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098Email: JC@ ADHCInvestor@ SOCIAL MEDIATWITTER: @ Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
19-05-2025
- Business
- Yahoo
American Diverisfied Holdings Corporation (ADHC) to Retain San Diego Based Bio Device Engineering Firm, Arete Bioscience, to Design GlucoGuard's Oral Diabetes Management Device
ADHC Receives Funding Commitment from Small Cap Hedge Fund to Finance GlucoGuard Development Del Mar, California--(Newsfile Corp. - May 19, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the company is to retain San Diego based bio engineering firm ARETE BIOSCIENCES, Inc. to design the GlucoGuard diabetes device pursuant to the recent FDA Breakthrough Device directive. Arete BioScience's team of scientists and biomechanical engineers have completed a review of GlucoGuard's foundational documentation including intellectual property, design schematics, and FDA application documentation. The team has devised a development protocol that will be initiated with the input and guidance of GlucoGuard's advisor Dr. Stephen Weber in order to facilitate the next step in the FDA approval process. Additionally, ADHC has received a funding commitment from a seasoned hedge fund that specializes in financing public companies. This funding will be NON-DILUTIVE following a financing model that is not detrimental to the trading environment of ADHC stock. This funding will be provided in one or more tranches based upon a "USE OF FUNDS" provided to the hedge fund. "Developments are rapidly coming to together as development partners are recognizing the potential of the GlucoGuard technology. The GlucoGuard team led by Advisor Dr. Weber, and co Founder Zach Smith are now in a position fully accelerate the development," commented ADHC. "In conjunction with the device engineering, the APP Development in partnership with DEXCOM Continuous Glucose monitoring technology in rapidly progressing," concluded ADHC. These relationships serve to build out the GlucoGuard footprint as an emerging biodevice technology providing a novel solution to the serious unmet challenge in managing HYPOGLECMIA in diabetic patients. More news on the DEXCOM partnership progression, how GlucoGuard is utilizing Artificial Intelligence in predicting Hypoglycemia and other key issues will be publicized in the near term. ABOUT ARETE BIOSCIENCES, Inc. Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space. Arete BioScience includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries. ABOUT DR. STEPHEN WEBER, MD Dr. Weber is currently an Assistant Professor at the Johns Hopkins School of Medicine. He previously served as a Medical Officer and Clinical Reviewer at The US Food and Drug Administration (FDA) and practiced medicine as an Orthopedic Surgeon for over 25 years. ABOUT GLUCOGUARD ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest. To view an enhanced version of this graphic, please visit: ABOUT THE DIABETES MARKET The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption. The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions. For more information, visit: Contact: Phone: John Cacchioli, CEOAmerican Diversified Holdings CorporationTelephone: (212) 537-5900Email: JC@ Social Media:TWITTER: @ Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
